World's Best Scientists 2026 revealed!

Overview

Henk M. Lokhorst is affiliated with VU University Medical Center in the Netherlands. Their research primarily spans the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. Within these disciplines, Lokhorst's work focuses on several subfields, including Molecular Biology, Cancer Research, Hematology, and Genetics.

Their research contributions cover a variety of topics related to cancer and hematological diseases. Key research areas include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer-related Molecular Mechanisms, Cancer Genomics and Diagnostics, Extracellular Vesicles in Disease, PI3K/AKT/mTOR Signaling in Cancer, and Myeloproliferative Neoplasms Diagnosis and Treatment.

Lokhorst has coauthored multiple scientific papers with frequent collaborators such as Thomas Hielscher, Hans Salwender, Peter Brossart, Marc S. Raab, and Jens Hillengaß.

The scientist has published articles in several peer-reviewed journals, including Cancer Cell, Blood Cancer Journal, and HemaSphere. Notable recent publications include:

  • Detection and localization of early- and late-stage cancers using platelet RNA, 2022, Cancer Cell
  • Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma, 2021, Blood Cancer Journal
  • Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial, 2024, HemaSphere

Best Publications

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Targeting CD38 with daratumumab monotherapy in multiple myeloma

    Henk M Lokhorst;Torben Plesner;Jacob P Laubach;Hareth Nahi

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

    Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

    Jakub Krejcik;Jakub Krejcik;Tineke Casneuf;Inger S. Nijhof;Bie Verbist

  • Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Saad Z. Usmani;Brendan M. Weiss;Torben Plesner;Nizar J. Bahlis

  • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    Kai Neben;Henk M. Lokhorst;Anna Jauch;Uta Bertsch

  • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos

  • International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.

    M Dimopoulos;E Terpos;R L Comenzo;P Tosi

  • Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome

    H.M. Lokhorst;A. Schattenberg;J.J. Cornelissen;M.H. J. van Oers

  • Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

    Annemiek Broyl;Dirk Hose;Henk Lokhorst;Yvonne de Knegt

  • Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

    Patrick W. B. Derksen;Esther Tjin;Helen P. Meijer;Melanie D. Klok

  • CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

    Inger S. Nijhof;Inger S. Nijhof;Tineke Casneuf;Jeroen van Velzen;Berris van Kessel

  • A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

    Henk M. Lokhorst;Bronno van der Holt;Sonja Zweegman;Edo Vellenga

  • Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

    Niels W. C. J. van de Donk;Maarten L. Janmaat;Tuna Mutis;Jeroen J. Lammerts van Bueren

  • Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

    Pierre Wijermans;Martijn Schaafsma;Fabian Termorshuizen;Rianne Ammerlaan

  • Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

    Pieter Sonneveld;Hartmut Goldschmidt;Laura Rosiñol;Joan Bladé

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

    Annemiek Broyl;Sophie L. Corthals;Joost L. M. Jongen;Bronno van der Holt

  • Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

    Shaji Kumar;Meletios A Dimopoulos;Efstathios Kastritis;Evangelos Terpos

Frequent Co-Authors

Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Tuna Mutis
Tuna Mutis Vrije Universiteit Amsterdam
Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Sagar Lonial
Sagar Lonial Emory University
Antonio Palumbo
Antonio Palumbo University of Turin
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Edo Vellenga
Edo Vellenga University Medical Center Groningen
Michele Cavo
Michele Cavo University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine goes beyond becoming a doctor. Today, there are numerous accessible online degree paths in healthcare. For those interested in managing patient records and information, rhit programs online offer a flexible way to gain certification in health information management.

If you want to enter the medical billing or coding sector, you can benefit from the cheapest medical coding certification online. These programs help you quickly qualify for essential support roles in healthcare facilities.

Aspiring advanced care providers can explore the cheapest online acute care nurse practitioner programs to build specialized skills and expand patient care responsibilities.

For those starting their nursing journey, nursing school online options are available, making it possible to study from home and achieve RN or BSN credentials.

Each of these online pathways offers affordable and convenient entry points into the expanding healthcare workforce, making them attractive options for students seeking flexibility and growth in their medical careers.

Best Scientists Citing Henk M. Lokhorst

Trending Scientists